Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Net Income towards Common Stockholders (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$37.4 million as the latest value for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 59.94% year-over-year to -$37.4 million; the TTM value through Dec 2025 reached -$122.9 million, down 23.89%, while the annual FY2025 figure was -$122.9 million, 25.52% down from the prior year.
  • Net Income towards Common Stockholders hit -$37.4 million in Q4 2025 for Sangamo Therapeutics, down from -$34.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $21.1 million in Q1 2023 and bottomed at -$114.5 million in Q2 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$42.5 million, with a median of -$43.6 million recorded in 2022.
  • Year-over-year, Net Income towards Common Stockholders plummeted 3062.33% in 2021 and then surged 148.01% in 2023.
  • Sangamo Therapeutics' Net Income towards Common Stockholders stood at -$37.5 million in 2021, then crashed by 38.71% to -$52.0 million in 2022, then dropped by 16.01% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 59.94% to -$37.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$37.4 million, -$34.9 million, and -$20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.